Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line

Oral Oncology

Volumn 40, Issue 7, 2004, Pages 679-687

  Supriatno, ^a   Harada, Koji ^a   Kawaguchi, Shin Ichi ^a   Onoue, Tomitaro ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antitumor activity; Gene therapy; Mutant type p27Kip1 gene; Oral cancer

Indexed keywords

ADENINE; CYTOSINE; GUANINE; METHIONINE; PROTEIN P27; PROTEIN P57; THREONINE; THYMINE; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL LYSATE; CELL MIGRATION; EXPRESSION VECTOR; GENE CONSTRUCT; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO CULTURE; METASTASIS; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE THERAPY; GENETIC VECTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 2542497844     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2004.01.002     Document Type: Article

References (36)

1. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer Res. 68:1996;67-108
2. Grana X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:1995;211-219
3. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163
4. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512
5. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22
6. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66
7. Kip1 protein: prognostic implications in primary breast cancer. Nature Med. 3:1997;227-230
8. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385
9. Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., et al. p27 expression and gastric carcinoma. Nature Med. 3:1997;593
10. Mineta H., Miura K., Suzuki I., Takebayashi S., Amano H., Araki K., et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer. 85:1999;1011-1107
11. Kip1 on the ability of invasion and metastasis of an oral cancer cell line. Oncol. Rep. 10:2003;527-532
12. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentino M., Draetta G.F., et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 2:1997;231-234
13. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T., et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269
14. Montagnoli A., Fiore F., Eytan E., Carrano A.C., Draetta G.F., Hershko A., et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 13:1999;1181-1189
15. Kip1. EMBO J. 16:1997;5334-5344
16. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated calorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942
17. Chen X., Ko L.J., Jayaraman L., Prives C. p53 levels, functional domains, and DNA damage determine the extents of the apoptotic response of tumor cells. Genes Dev. 10:1996;2438-2451
18. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85:1996;707-720
19. Kip1 on resistance of tumor cells to anti-cancer agents. Nature Med. 2:1996;1204-1210
20. Katayose Y., Kim M., Rakkar A.N.S., Li Z., Cowan K.H., Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res. 57:1997;5441-5445
21. Kip1 safeguards against inflammatory injury. Nature Med. 4:1998;575-580
22. Durand B., Gao F.B., Raff M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J. 16:1997;306-317
23. Kip1. Proc. Natl. Acad. Sci. USA. 95:1998;15158-15160
24. Kip1-deficient mice. Cell. 85:1996;733-744
25. Kip1 is haplo-insufficient for tumor suppression. Nature (Lond.). 386:1998;177-180
26. Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cells. Oncogene. 14:1997;2283-2289
27. Kip1: a strategy for breast cancer gene therapy. J. Natl. Cancer Inst. 90:1998;1836-1838
28. Kip1 induces growth arrest of lung cancer cell lines and suppresses the growth of established lung cancer xenografts. Lung Cancer. 31:2001;149-155
29. Kip1 induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol. 38:2002;730-736
30. Park K.H., Seol J.Y., Kim T.Y., Yoo C.G., Kim Y.W., Han S.K., et al. An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res. 61:2001;6163-6169
31. Kip1 gene transfer on head and neck squamous cell carcinoma cell lines. Head Neck. 25:2003;44-49
32. Kip1 threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells. Oncology. 63:2002;398-404
33. Kip1 induces growth arrest and apoptosis mediated by changes of pRb expression in lung cancer cell lines. Int. J. Cancer. 88:2000;377-383
34. Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene. 15:1997;2991-2997
35. Kip1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene. 18:1999;1663-1676
36. Kip1. J. Clin. Invest. 103:1999;597-604